Journal of Pain and Symptom Management
Volume 19, Issue 6 , Pages 446-456 , June 2000

High Level of Fatigue in Lymphoma Patients Treated With High Dose Therapy

  • Heidi Knobel, MD

      Affiliations

    • Unit for Applied Clinical Research, Norwegian University of Science and Technology, Trondheim, Norway
    • Corresponding Author InformationAddress reprint requests to: Heidi Knobel, MD, Unit for Applied Clinical Research, The Faculty of Medicine, Norwegian University of Science and Technology, Trondheim University Hospital, N-7006 Trondheim, Norway
    • ,
  • Jon Håvard Loge, MD

      Affiliations

    • Unit for Applied Clinical Research, Norwegian University of Science and Technology, Trondheim, Norway
    • Department of Behavioral Sciences in Medicine, University of Oslo, Oslo, Norway
    • ,
  • Tone Nordøy, MD

      Affiliations

    • Department of Oncology, Tromsø University Hospital, Tromsø, Norway
    • ,
  • Arne L. Kolstad, MD, PhD

      Affiliations

    • Department of Oncology, Tromsø University Hospital, Tromsø, Norway
    • ,
  • Terje Espevik, MD, PhD

      Affiliations

    • The Faculty of Medicine, and Institute of Cancer Research, Norwegian University of Science and Technology, Trondheim, Norway
    • ,
  • Stein Kvaløy, MD, PhD

      Affiliations

    • Unit for Applied Clinical Research, Norwegian University of Science and Technology, Trondheim, Norway
    • The Norwegian Radium Hospital, Oslo, Norway
    • Palliative Care Unit, Department of Oncology, Trondheim University Hospital, Trondheim, Norway
    • ,
  • Stein Kaasa, MD, PhD

      Affiliations

    • Unit for Applied Clinical Research, Norwegian University of Science and Technology, Trondheim, Norway
    • The Norwegian Radium Hospital, Oslo, Norway
    • Palliative Care Unit, Department of Oncology, Trondheim University Hospital, Trondheim, Norway

,Accepted 14 July 1999.

References 

  1. Sociè G, Henry-Amar M, Divergie A, Esperou-Bordeau H, Ribaud P, Traineau R, et al. Malignant diseases after allogenic bone marrow transplantation (an updated overview). Nov Rev Fr Hematol. 1994;36(Suppl 1):75–77
  2. Vose JM, Kennedy BC, Bierman PJ, Kessinger A, Armitage JO. Long-term sequelae of autologous bone marrow or peripheral stem cell transplantation for lymphoid malignancies. Cancer. 1992;69:784–789
  3. van Dam FSAM, Schagen SS, Muller MJ, Boogerd W, vd Wall E, Droogleever Fortuyn ME, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer (high-dose versus standard-dose chemotherapy). J Natl Cancer Inst. 1998;90:210–218
  4. Deeg JH. Delayed complications and long-term effects after bone marrow transplantation. Bone Marrow Transplant. 1990;4:641–657
  5. Hjermstad MJ, Kaasa S. Quality of Life in adult cancer patients treated with bone marrow transplantation - a review of the literature. Eur J Cancer. 1995;31A:163–173
  6. Hjermstad MJ, Evensen SA, Kvaløy SO, Kaasa S. Health related quality of life after allogenic or autologous stem cell transplantation (a prospective study). J Clin Oncol. 1999;17:706–718
  7. Hjermstad MJ, Holthe H, Evensen SA, Fayers P, Kaasa S. Do patients who are treated with stem cell transplantation have a health related quality of life comparable to the general population after one year?. Bone Marrow Transpl. 1999;124:911–918
  8. Andrykowski MA, Carpenter JS, Greiner CB, Altmeier EM, Burish TG, Antin JH, et al. Energy level and sleep quality following bone marrow transplantation. Bone Marrow Transplant. 1997;20:669–679
  9. Aaronsen NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NI, et al  The European Organization for Research and Treatment of Cancer QLQ-C30 (A quality of life instrument for use in international clinical trials in oncology). J Natl Cancer Inst. 1993;85:365–376
  10. Wessely S. The measurement of fatigue and chronic fatigue syndrome. J R Soc Med. 1992;85:189–190
  11. Wettergren L, Langius A, Björkholm M, Björvell H. Physical and psychosocial functioning in patients undergoing autologous bone marrow transplantation - a prospective study. Bone Marrow Transplant. 1997;20:497–502
  12. Bush NE, Haberman M, Donaldson G, Sullivan KM. Quality of life of 125 adults surviving 6–18 years after bone marrow transplantation. Soc Sci Med. 1995;40:479–490
  13. Andrykowski MA, Altmaier EM, Barnett RL, Otis ML, Gingrich R, Henslee-Downey PJ. The quality of life in adult survivors of allogenic bone marrow transplantation (correlates and comparison with matched renal transplant recipients). Transplantation. 1990;50:399–406
  14. Belec RH. Quality of life (perceptions of long-term survivors of bone marrow transplantation). Oncol Nurs Forum. 1992;19:31–37
  15. Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D, et al. Development of a fatigue scale. J Psychosom Res. 1993;37:147–153
  16. Loge JH, Ekeberg Ø, Kaasa S. Fatigue in the general Norwegian population (Normative data and associations). J Psychosom Res. 1998;45:53–65
  17. Loge JH, Abrahamsen AF, Ekeberg Ø, Kaasa S. Hodgkins disease survivors more fatigued than the general population. J Clin Oncol. 1999;17:253–261
  18. Richardson A. Fatigue in cancer patients (a review of the literature). Eur J Cancer Care. 1995;4:20–32
  19. Smets EMA. Fatigue in cancer patients. Br J Cancer. 1993;68:220–224
  20. Darko D, McCutchan A, Kripke D, Gillin J, Golchan S. Fatigue, sleep disturbance, disability, and indicies of progression of HIV infection. Am J Psychiatry. 1992;194:514–519
  21. Wysenbeek AJ, Leibovici L, Weinberger A, Guedj D. Fatigue in systemic lupus erythematosus. Prevalence and relation to disease expression. Br J Rheumatol. 1993;32:633–635
  22. Greenberg DB, Gray JL, Mannis CM, Eisenthal S, Carey M. Treatment-related fatigue and serum interleukin-1 levels in patients during external beam irradiation for prostate cancer. J Pain Symptom Manage. 1993;8:196–200
  23. Arnason BGW. Nervous system - Immune System Communication. Rev Infec Diseases. 1991;13(Suppl 1):134–137
  24. Shimmer A, Quatremain M, Imre K, Ali V, McCrae J, Stewart K, et al. Ovarian function after autologous bone marrow transplantation. J Clin Oncol. 1998;16:2359–2363
  25. Todd BD. Pancreatic carcinoma and low serum testosterone; a correlation secondary to cancer cachexia?. Eur J Surg Oncol. 1988;14:199–202
  26. Chlebowski RT, Heber D. Hypogonadism in male patients with metastatic cancer prior to chemotherapy. Cancer Res. 1982;42:2495–2498
  27. Wessely S, Powell R. Fatigue syndromes (a comparison of chronic “postviral” fatigue with neuromuscular and affective disorders). J Neurol Neurosurg Psychiatry. 1989;52:940–948
  28. Fayers P, Aaronsen N, Bjordal K, Sullivan M. EORTC QLQ-C30 Scoring Manual. EORTC Quality of life study group. Brussels, Belgium, 1995.
  29. Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S. Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (The QLQ-C30 (+3)). J Clin Oncol. 1998;16:1188–1196
  30. Aarden LA, de Groot ER, Shaap OL, Landsdorp PM. Production of hybridoma growth factor by human monocytes. Eur J Immunol. 1987;7:1441
  31. Mosman T. Rapid colorimetric assay for cellular growth and survival (application to proliferation and cytotoxic assays). J Immunol Methods. 1983;65:55
  32. Espevik T, Nissen-Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from hman monocytes. J Immunol Methods. 1986;95:99
  33. Liabakk NB, Sundan A, Lien E, Lacgried A, Bombac MP, Ranges G, et al. The release of p55 receptor from U937 cells studied by a new p55 immunoassay. J Immunol Methods. 1993;163:145–154
  34. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related-quality-life-scores. J Clin Oncol. 1998;16:139–144
  35. Fobair P, Hoppe RT, Bloom J, Cox R, Varghese A, Spiegel D. Psychosocial problems among survivors of Hodgkins disesase. J Clin Oncol. 1986;4:805–814
  36. Sutherland HJ, Fyles GM, Adams G. Quality of life following bone marrow transplantation (a comparison of patients reports with population norms). Bone Marrow Transplant. 1997;17:1129–1136
  37. Denz H, Orth B, Wiess G, Gallati H, Herrmann R, Huber P, et al. Serum soluble Tumor Necrosis Factor receptor 55 is increased in patients with heamatological neoplasias and is associated with immune activation and weight loss. Eur J Cancer. 1993;29A(16):2232–2235
  38. Warzocha K, Salles G, Bienvenu J, Bastian Y, Dumontet C, Renard N, et al. Tumor Necrosis Factor ligand-receptor system can predict treatment outcome in lymphoma patients. J Clin Oncol. 1997;15:499–508
  39. Salles G, Bienvenu J, Bastion Y, Barbier Y, Doche C, Warsocha K, et al. Elevated circulating levels of TNFα and its soluble receptor are associated with an adverse prognosis in lymphoma patients. Br J Haematol. 1960;93:352–359
  40. Patarca R, Klimas NG, Lugtendorf S, Antoni M, Fletcher MA. Dysregulated expression of tumor necrosis factor in chronic fatigue syndrome (interrelations with cellular sources and patterns of soluble immune mediator expression). Clin Infect Dis. 1994;18(Suppl 1):147–153
  41. Landay AL, Jessop C, Lennete ET, Mevy JA. Chronic fatigue syndrome (clinical conditions associated with immune activation). Lancet. 1991;338:707–712
  42. Linde A, Andersson B, Svenson SB, Ahrne H, Carlsson MP, Forsberg P, et al. Serum levels of lymphokines and soluble cellular receptors in primary Epstein–Barr virus infection and in patients with chronic fatigue syndrome. J Infect Dis. 1992;165:994–1000
  43. Morant R. Asthenia (an important symptom in cancer patients). Cancer Treat Rev. 1996;22(Suppl.A):117–221
  44. Keilholz U, Korbling M, Fehrentz D, Bauer H, Hunstein W. Long term endocrine toxicity of myeloablative treatment followed by autologous bone marrow / blood-derived stem cell transplantation in patients with malignant lymphohematopoietic disorders. Cancer. 1989;64:641–645
  45. Studd JWW, Smith RNJ. Oestradiol and testosterone implants. Baillieres Clin Endocrinol Metab. 1993;7:203–223
  46. Cull A, Hay C, Love SB, Mackie M, Smets E, Stewart M. What do cancer patients mean when they complain of concentration and memory problems?. Br J Cancer. 1996;74:1674–1679
  47. van Tulder MW, Aaronson NK, Bruning PF. The quality of life of long term survivors of Hodgkins disease. Ann Oncol. 1994;5:153–158
  48. Andrykowski MA, Altmaier EM, Barnett RL, Burish TG, Gingrich R, Henslee-Downey PJ. Cognitive dysfunction in adult survivors of allogenic marrow transplantation (relationship to dose of total body irradiation). Bone Marrow Transplant. 1990;6:269–276
  49. Loge JH, Abrahamsen AF, Ekeberg Ø, Kaasa S. Fatigue and psychiatric morbidity among Hodgkin's disease survivors. J xcPain Symp Manag. 2000;19:91–99

PII: S0885-3924(00)00144-5

Journal of Pain and Symptom Management
Volume 19, Issue 6 , Pages 446-456 , June 2000

Article Tools